Barcelona-based biotech startup Biorce, which uses AI to accelerate clinical trials, has raised $52 million in a Series A round, bringing its total funding to approximately $62 million.
- Biorce was founded in 2022 in Barcelona by Pedro Coelho, Diogo Pisoeiro, Clara Bernardes, and José Faria. The company builds AI software for the clinical trials industry, aimed at helping pharmaceutical companies, biotech firms, and contract research organisations plan and run studies more efficiently.
- Its platform, Aika, uses machine learning trained on hundreds of thousands of past clinical trials to support protocol design, feasibility assessments, regulatory preparation, and patient recruitment.
- The system produces documented, traceable outputs that teams can use in regulatory submissions, while keeping decision-making with clinical experts. By addressing common sources of delay such as protocol amendments and poor trial design, Biorce seeks to reduce costs and shorten the time needed to bring new medicines to patients.
- In November 2024, Biorce secured €3.5 million in a seed round led by YZR Capital and Mustard Seed Maze, followed by an additional €5 million in funding in July 2025.
Details of the deal
- The $52 million Series A was led by DST Global Partners with participation from Norrsken VC, YZR Capital, Mustard Seed Maze, and angel investors including Arthur Mensch, Albert Nieto, Paulo Rosado, and Nik Storonsky.
- The fresh capital will enable the firm to expand internationally, with a strong focus on entering the US market, while significantly growing its team and accelerating the development of its AI-driven clinical trial platform.
- The funding will also support new product features, increased R&D investment, and the opening of a new development hub, helping the company run faster, more efficient clinical trials and bring new treatments to patients sooner.
“This $52 million round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives. Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate," claims Pedro Coelho, CEO of Biorce.
